BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Danny Rischin, Professor
University of Sydney
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
- Royal Brisbane and Women'S Hospital
Brisbane, Queensland, Australia
- Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
- Christchurch Hospital
Christchurch, Canterbury, New Zealand
- University of Chicago
Chicago, Illinois, United States
- Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2012
- Primary completion
- 31 Jul 2014
- Completion
- 31 Oct 2014
- Last update posted
- 23 Dec 2015
- Registered enrollment
- 0
- Registry id
- NCT01624493
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.